Among devices and related products studied are intrathecal drug delivery systems (IDDS), intrauterine devices (IUDs), imaging agents, genomic testing assays.

 

 PHARMACEUTICAL MARKET RESEARCH REPORTS BASED IN SCIENCE

Immune disorders & deficiencies

Medical devices

© 2014-2018 Clarity Pharma Research LLC  |  All Rights Reserved​ Privacy Policy
To learn more about our services, call (864) 208-0078 or contact information@claritypharma.com.
​S
ubscribe to our newsletter at: http://eepurl.com/ovQcb

Related Articles or Presentations 

  • Rheumatology and Therapy, co-authors, article on utilization patterns and medical resource use of a product among patients with rheumatologic diseases (December 2017; online October 2017) Article
  • Urology Practice, retrospective chart review analysis of genomic assay used in men newly diagnosed with prostate cancer (November 2015; online July 2015) Abstract
  • Sargramostim (GM-CSF) as Immunotherapy (PDF)
  • HIV / AIDS Anemia (PDF)
  • Undiagnosed Chronic Kidney Disease Among Rheumatoid Arthritis Patients (PDF)

We have long studied immune treatment and response. For more than 15 years we studied colony stimulating factors (CSFs) and have published articles about immunotherapy. We also have studied the use of IVIg / SCIg to treat immunodeficient patients.

 

HIV / AIDS – Our firms scientists have done extensive research in the HIV / AIDS market for two decades, including several studies on AIDS-related infections.

 

MS Our experience with multiple sclerosis extends back to the clinical internship in a Virginia state hospital of Clarity’s founder, Dr. Jack Gallagher, during which he worked with more than 100 MS patients and adults. Clarity since has studied various MS (and RRMS) treatments, including biologics, steroids, and interferons. 

 

Psoriasis, Psoriatic Arthritis – We have conducted several studies on treatment algorithms (e.g., biologics vs. various other treatments) by  location, severity, and efficacy.

 

RA – We have studied RA as well as important subpopulations of the disorder, e.g., RA patients with chronic kidney disease or anemia


Other disease areas: dermatomyositis/polymyositis (DM/PM) and  systemic lupus erythematosus (SLE)